Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Thoracic 2Genitourinary 2Gastrointestinal 2Head & Neck 1CNS 1

Conditions

Prostatic Neoplasms 2

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × paclitaxel poliglumex × Genitourinary × Clear all
NCT00459810 2017-04-28

Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
21 enrolled 8 charts
Genitourinary

Prostatic Neoplasms

NCT00446836 2016-03-17

Efficacy and Safety Study of Xyotax to Treat Prostate Cancer

The Methodist Hospital Research Institute

Phase 2 Completed
29 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡